iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in t…
FAIL · Does not pass the screen
110.37 USD
Screen close, 2026-10-02 · not a live quote Last reviewed 5 days ago
Screened 2026-10-02 · the tape above runs as of 09:14 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 110.37 against the desk's fair-value range, base estimate 102.10, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price110.37 USD
Fair value102.10
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Markdown110.380.0% to today ✓
2026-09-02Read Markup119.15-7.4% to today
2026-08-02Read Markdown110.88-0.5% to today ✓
2026-07-02Read Distribution113.65-2.9% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
iRhythm Holdings, Inc. holds its Markdown at $110.37. Elevated stress, defensive posture warranted, held for 205 days.
As held on the ledger · 2026-10-02
Phase
Markdown · caution
Quantitative state
Elevated stress, defensive posture warranted, held for 205 days
Price at the screen
$110.37
Valuation
N/A trailing · 90.95 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.32
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
71.68%
Below 33%
Interest-bearing debt is 71.7% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
34.09%
Below 33%
Interest-bearing cash and securities are 34.1% of assets, above the one-third limit.
Fail
Receivables
30.56%
Below 49%
Money owed to the company is 30.6% of assets, under the 49% limit.
Pass
Revenue purity
2.88%
Below 5%
Only 2.9% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
iRhythm Holdings,'s business is in a permissible area, but its interest-bearing debt is about 72% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-07. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-10-02 screen. The gold marker is the market price at the same screen. The price runs 7.5% above the base estimate.
Third-party analyst targets: 14 covering, consensus Strong Buy. The average target sits +61% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-02 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Heart patches track rhythms but price outruns value
Imagine strapping on a small patch that records every heartbeat for up to two weeks, then spotting dangerous skips before they turn serious. iRhythm built that service around its Zio device and revenue is still climbing 26 percent. Yet the company posts a negative 4 percent profit margin and minus 22 percent return on equity, so growth has not reached the bottom line.
At 104 times forward earnings the shares trade above our fair value with an 8 percent negative margin of safety. Strong analyst targets sit far higher, but our screen finds no opportunity once the multiple and missing profits are weighed together. The medical-device story is clear, the economics are not.
High multiples leave scant room for the usual slips in regulatory approvals or reimbursement changes. Until margins turn consistently positive the valuation rests on hope rather than delivered returns. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
IRTC trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Markdown · changed$110.38-7.4%Entry 6
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 7.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 23%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (14 analysts) rates it strong buy, with a mean price target of $181.
2026-09-02Markup · changed$119.15+7.5%Entry 5
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 23%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (14 analysts) rates it strong buy, with a mean price target of $181.
2026-08-02Markdown · changed$110.88-2.4%Entry 4
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 23%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (14 analysts) rates it strong buy, with a mean price target of $181.
2026-07-18Distribution$113.65+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 23%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (14 analysts) rates it strong buy, with a mean price target of $181.
2026-07-03Distribution$113.65+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Distribution$113.65Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
